In 2020, Bristol Myers Squibb launched the Patient Expert Engagement Resource (PEER) program, which has benefited from the full support of the company’s Chief Medical Officer throughout its existence.
As a first of its kind collaboration with experts at patient advocacy organizations, PEER systematically and consistently incorporates patient community perspectives throughout the drug discovery and development process.
“One fundamental way we’re making progress toward clinical and real-world success is by applying a patient-centric lens to every stage of clinical development,” said Anne Kerber, senior vice president, head of development, hematology, oncology and cell therapy, for BMS. “We do this by listening to what patients and their communities need and bringing their voices into our development process from the start through our PEER program.”
Since the inception of the PEER program, BMS has collaborated with over 120 patient advocacy organizations on a range of insight-gathering activities with a bold mandate that all Phase 3 clinical trial protocols receive PEER feedback.
And the feedback has made a real difference in our clinical trials. For example, the inclusion criteria of a key trial protocol were amended based on the feedback received by Canada-based Save your Skin Foundation, a patient-led not for profit group dedicated to the fight against non-melanoma skin cancers, melanoma and ocular melanoma. In another example, feedback from two organizations in the UK resulted in changes to informed consent and assent documents for a study in Crohn’s disease. The PEER feedback not only produced more patient-friendly clinical trial documents, but also satisfied regulatory requirements for inclusion of patient voice set by the UK Health Research Authority.
“PEER sits at the intersection of cutting-edge science, innovation and the patient perspective,” said Steven Unger, senior director, Early Advocacy Engagement and PEER Program Lead at BMS. “Our partners at patient advocacy groups represent patient communities, and also have sophisticated capabilities, oftentimes conducting critical research and tapping into diverse or underrepresented patient populations. Ensuring they have a seat at the table throughout development benefits and accelerates research, ultimately helping future patients."
BMS remains committed to transforming patients’ lives through science, and that mission cannot be accomplished alone. PEER continues to grow, connecting more teams and functions to patient advocacy input from early research through commercialization.
Looking ahead, BMS is also building an internal Patient Insight Engine, a technology platform designed to bring the learnings captured through PEER to teams across the company at scale.
The goal is simple: ensure patient and care partner insights inform decisions across BMS, wherever those decisions are made.